Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

The demand for generic products is high in the pharmaceutical market in Latin America. Moreover, majority of pharmaceutical companies are gradually outsourcing manufacturing activities to contract manufacturing organizations (CMO).

Statistics:

Latin America Pharmaceutical Products CMO Market is estimated to account for US$ 13,266.5 Mn in terms of value by the end of 2027.

Latin America Pharmaceutical Products CMO Market: Drivers

Increasing prevalence of chronic disorders is expected to propel growth of Latin America Pharmaceutical Products CMO Market over the forecast period. For instance, according to Incidência de Câncer no Brasil, the estimated number of new cases of cancer was 600,000, excluding cases of non-melanoma skin cancer during 2018-2019 biennium, in Brazil.

Moreover, increasing vaccination drives are also expected to aid in growth of the market. For instance, in March 2020, Brazil initiated its National Flu Vaccination Campaign in three phases against influenza. The vaccine is indicated for anyone over 6 months of age, except those who have had allergic reactions at previous doses.

Statistics:

Brazil held dominant position in Latin America Pharmaceutical Products CMO Market in 2019, accounting for 38.6% share in terms of value, followed by Mexico and Argentina, respectively

Figure 1: Latin America Pharmaceutical Products CMO Market Share (%) Value, By Region, 2019

Latin America Pharmaceutical Products CMO  | Coherent Market Insights

Latin America Pharmaceutical Products CMO Market: Restraints

The pharmaceutical industry in Mexico does not operate through an established system of reimbursement and there is minimal reimbursement offered outside the hospital setting. Reimbursement is limited to generic drugs, based on health technology assessment and to the under privileged population. Such scenario is expected to hinder growth of Latin America Pharmaceutical Products CMO Market.

Weak or ambiguity in patent laws is also expected to limit growth of the market. Different countries in Latin America have adopted different approaches for intellectual property protection. Ambiguity also prevails regarding pricing of drugs. For instance, prices of public sector pharmaceutical drugs in Latin America varied than those sold through the private sector.

request-sample

Latin America Pharmaceutical Products CMO Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 13,266.5 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 14.8% 2027 Value Projection: US$ 40,070.3 Mn
Geographies covered:
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
Segments covered:
  • By Product Type: API and Ingredients, Finished Dosage Form, Pharmaceutical Packaging
Companies covered:

BASF SE, Bayer AG, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Pisa Farmacéutica, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, Ferring Pharmaceuticals, Inc., and Landsteiner Scientific.

Growth Drivers:
  • Increasing prevalence of chronic diseases
Restraints & Challenges:
  • Stringent Regulation

Latin America Pharmaceutical Products CMO Market: Opportunities 

Growing medical tourism in Latin America is expected to offer lucrative growth opportunities for players in the market. For instance, according to Tourism of the Federal District, Mexico City, in 2018, Tijuana received 1.7 million patients and companions from the U.S. and Canada generating a revenue of US$ 600 million.

Moreover, integration of public and private healthcare sector in Latin America may lead to revival of a weak sector in the region, thereby aiding in growth of the market.  

Statistics:

Latin America Pharmaceutical Products CMO Market was valued at US$ 13,266.5 Mn in 2019 and is forecast to reach a value of US$ 40,070.3 Mn by 2027 at a CAGR of 14.8% between 2020 and 2027.

Figure 2: Latin America Pharmaceutical Products CMO Market Value (US$ Mn), 2016 - 2027

Latin America Pharmaceutical Products CMO  | Coherent Market Insights

Market Trends/Key Takeaways

Major pharmaceutical companies are focused on approval and launch of COVID-19 test kits. For instance, in February 2020, Osang Healthcare received European certification (CE-IVD) for GeneFinder, a test kit for the new coronavirus, and the company has commercialized the product in Italy, Romania, Morocco, Brazil, and Russia.

The coronavirus pandemic has adversely impacted the healthcare system in Latin America. As of May 07, 2020, there have been 26,025 confirmed cases of COVID-19 with 2,507 deaths in Mexico as reported to the World Health Organization. The lockdown implemented in several countries in Latin America is expected to have mixed impact on the market. 

Figure 3: Value Chain Analysis -

Latin America Pharmaceutical Products CMO  | Coherent Market Insights

Latin America Pharmaceutical Products CMO Market: Competitive Landscape

Major players operating in Latin America Pharmaceutical Products CMO Market include, BASF SE, Bayer AG, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Pisa Farmacéutica, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, Ferring Pharmaceuticals, Inc., and Landsteiner Scientific.

Latin America Pharmaceutical Products CMO Market: Key Developments

Major players in the market are focused on adopting partnership strategies to enhance their market share. For instance, in March 2019, Pfizer, Inc. partnered with Unión Latinoamerica Contra el Cáncer de la Mujer - Latin American Union Against Cancer of Women, to launch the personal guide “Me and Metastatic Breast Cancer”.

Major players in the market are also focused on R&D of new products to expand their product portfolio. For instance, in December 2019, FerGene, a new gene therapy company formed as an alliance between Ferring Pharmaceuticals and Blackstone Life Sciences, announced positive results from a clinical trial that assessed the efficacy of nadofaragene firadenovec (rAd-IFN/Syn3), an investigational gene therapy, for the treatment of high-grade, Bacillus Calmette-Guérin  unresponsive non-muscle invasive bladder cancer.

Pharmaceutical Products CMO provide wide range of manufacturing services, which include contract packaging, quality testing, and development service to pharmaceutical and biotechnology industries. Contract manufacturing organizations provide services from development of biologics to commercial scale production. Increasing prevalence of chronic disorders is expected to propel growth of Latin America Pharmaceutical Products CMO Market over the forecast period. Moreover, increasing expansion of international pharmaceutical companies in Latin America is expected to propel growth of Latin America Pharmaceutical Products CMO market during the forecast priod.

Key features of the study:

  • This report provides in-depth analysis of the Latin America Pharmaceutical Products CMO market  and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the global Latin America Pharmaceutical Products CMO market  based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include, BASF SE, Bayer AG, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Pisa Farmacéutica, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, Ferring Pharmaceuticals, Inc., and Landsteiner Scientific.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global Latin America Pharmaceutical Products CMO market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Latin America Pharmaceutical Products CMO market

Detailed Segmentation:

  • Latin America Pharmaceutical Products CMO Market, By Product Type:
    • API and Ingredients
    • Finished Dosage Form
    • Pharmaceutical Packaging
  • Latin America Pharmaceutical Products CMO Market, By Country:
    • Brazil
      • By Product Type:
        • API and Ingredients
        • Finished Dosage Form
        • Pharmaceutical Packaging
    • Mexico
      • By Product Type:
        • API and Ingredients
        • Finished Dosage Form
        • Pharmaceutical Packaging
    • Argentina
      • By Product Type:
        • API and Ingredients
        • Finished Dosage Form
        • Pharmaceutical Packaging
    • Rest of Latin America
      • By Product Type:
        • API and Ingredients
        • Finished Dosage Form
        • Pharmaceutical Packaging
  • Company Profiles
    • BASF SE *
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Overview
      • Strategies
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer, Inc.
    • Pisa Farmacéutica
    • Fresenius SE & Co. KGaA
    • Takeda Pharmaceutical Company Limited
    • Ferring Pharmaceuticals, Inc.
    • Landsteiner Scientific
  • “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Country
      • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Highlights
    • Product launch
    • PEST Analysis
    • Technological Advancements
    • Regulatory Scenario
    • Mergers and Acquisitions
  4. Latin America Pharmaceutical Products CMO Market, By Product Type, 2019 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • API and Ingredients
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Finished Dosage Form
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Pharmaceutical Packaging
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  5. Latin America Pharmaceutical Products CMO Market, By Country, 2019 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2026
    • Brazil
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
    • Mexico
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
    • Argentina
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
    • Rest of Latin America
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Mn)
  6. Competitive Landscape
    • Company Profiles
      • BASF SE
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bayer AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Boehringer Ingelheim GmbH
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • F. Hoffmann-La Roche Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pisa Farmacéutica
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Fresenius SE & Co. KGaA
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Takeda Pharmaceutical Company Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Ferring Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Landsteiner Scientific
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
  7. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 16 market data tables and 10 figures on “Latin America Pharmaceutical Products CMO Market - Global forecast to 2027”.

Frequently Asked Questions

The Latin America Pharmaceutical Products CMO market size was valued at US$ 13,266.5 million in 2019 and is estimated to exhibit a CAGR of 14.8% between 2020 and 2027.
API and Ingredients segment held the major market share in 2019 owing to an increasing manufacturing and demand for drugs for treating chronic diseases during the forecast period.
Major factor driving the growth of Latin America Pharmaceutical Products CMO market during the forecast period increasing prevalence of chronic, increasing demand for drugs, and adoption of expansion strategies from major companies.
Major factors hampering the growth of the Latin America Pharmaceutical Products CMO market during the forecast period constitutes of low investment in healthcare industry and stringent regulations.
Brazil Pharmaceutical Products CMO market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are BASF SE, Bayer AG, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Pisa Farmacéutica, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, Ferring Pharmaceuticals, Inc., and Landsteiner Scientific.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner